Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.

MLA

Mill, Christopher P., et al. “Effective Therapy for AML with RUNX1 Mutation by Cotreatment with Inhibitors of Protein Translation and BCL2.” Blood, vol. 139, no. 6, Feb. 2022, pp. 907–21. EBSCOhost, https://doi.org/10.1182/blood.2021013156.

APA

Mill, C. P., Fiskus, W., DiNardo, C. D., Birdwell, C., Davis, J. A., Kadia, T. M., Takahashi, K., Short, N., Daver, N., Ohanian, M., Borthakur, G., Kornblau, S. M., Green, M. R., Qi, Y., Su, X., Khoury, J. D., & Bhalla, K. N. (2022). Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood, 139(6), 907–921. https://doi.org/10.1182/blood.2021013156

Chicago

Mill, Christopher P, Warren Fiskus, Courtney D DiNardo, Christine Birdwell, John A Davis, Tapan M Kadia, Koichi Takahashi, et al. 2022. “Effective Therapy for AML with RUNX1 Mutation by Cotreatment with Inhibitors of Protein Translation and BCL2.” Blood 139 (6): 907–21. doi:10.1182/blood.2021013156.